AstraZeneca (LON:AZN) Sets New 52-Week High – Should You Buy?

AstraZeneca PLC (LON:AZN) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as £148.18 and last traded at £148.18, with a volume of 418815344 shares traded. The stock had previously closed at £141.64.

Analysts Set New Price Targets

Several brokerages have recently commented on AZN. Citigroup began coverage on AstraZeneca in a report on Tuesday, January 27th. They set a “buy” rating and a £170 target price for the company. Jefferies Financial Group restated a “buy” rating and set a £150 price objective on shares of AstraZeneca in a report on Monday, November 10th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a research report on Thursday, January 15th. Finally, Shore Capital Group restated a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of £145.83.

AstraZeneca Trading Up 1.5%

The company has a market cap of £234.46 billion, a PE ratio of 25.12, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The company has a 50 day simple moving average of £138.37 and a two-hundred day simple moving average of £128.44.

Insider Buying and Selling

In related news, insider Nazneen Rahman sold 297 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total transaction of £40,083.12. Insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.